Retatrutide 20mg

Retatrutide | 20mg

The next generation of metabolic research has arrived. Retatrutide is a groundbreaking triple hormone receptor agonist developed by Eli Lilly that simultaneously activates three key metabolic pathways — GLP-1, GIP, and glucagon receptors — in a single molecule. Where earlier compounds target one or two receptors, Retatrutide’s three-lane mechanism delivers a more comprehensive and potent approach to metabolic regulation than anything that has come before it.

Currently progressing through Phase 3 clinical trials under Eli Lilly’s TRIUMPH program, Retatrutide is one of the most closely watched compounds in metabolic science today.

What Research Suggests Retatrutide May Support:

Significant Weight Reduction — Phase 2 clinical trials produced average weight losses of 17.5% at 24 weeks and 24.4% at 48 weeks — results that exceed those seen with both semaglutide and tirzepatide in comparable timeframes, positioning Retatrutide as potentially the most effective pharmacological weight loss compound studied to date.

Appetite Regulation & Satiety — Through its GLP-1 receptor activity, Retatrutide slows gastric emptying and reduces appetite, with clinical trial participants consistently reporting earlier satiety, reduced hunger, and greater control over eating behaviour within the first weeks of research protocols.

Blood Sugar & Glycaemic Control — Research demonstrates meaningful reductions in fasting plasma glucose and HbA1c levels, with studies in both diabetic and non-diabetic subjects pointing to significant improvements in insulin sensitivity and long-term glycaemic management.

Fat Metabolism & Lipolysis — The addition of glucagon receptor agonism sets Retatrutide apart from its predecessors by directly enhancing fat oxidation and lipolysis in adipose tissue — encouraging the body to burn stored fat rather than simply suppressing the appetite that leads to its accumulation.

Cardiovascular Risk Reduction — Phase 3 data has shown meaningful reductions in non-HDL cholesterol, triglycerides, high-sensitivity C-reactive protein, and systolic blood pressure — pointing to a broad cardiometabolic benefit profile extending well beyond weight loss alone.

Joint Health & Mobility — In the landmark TRIUMPH-4 Phase 3 trial, Retatrutide delivered not only significant weight reduction but also substantial improvements in knee pain and physical function in subjects with osteoarthritis — highlighting its potential as a multi-system metabolic therapy.

Liver Health — Research indicates Retatrutide may reduce liver fat and address markers of metabolic dysfunction-associated steatotic liver disease, with dedicated Phase 3 trials currently underway to explore this application further.

For research purposes only. Not approved for human therapeutic use. Always consult a qualified healthcare professional.